Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

   Recruiting · Phase 1 · Advanced Solid Tumor

   NCT06598800 · Beone Medicines Ltd. · 3 U.S. investigators

   $363,653research payments

2. A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

   Recruiting · Phase 2 · Cervical Dystonia

   NCT06937931 · Ipsen Innovation · 8 U.S. investigators

   $363,581research payments

3. A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

   Completed · Phase 3 · Lichen Simplex Chronicus

   NCT06687967 · Sanofi US Services Inc. · 13 U.S. investigators

   $361,856research payments

4. Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

   Active, not recruiting · Not applicable · Tachycardia, Ventricular

   NCT04798768 · Boston Scientific Corporation · 15 U.S. investigators

   $359,843research payments

5. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

   Completed · Phase 1 · Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

   NCT03739931 · ModernaTX, Inc. · 7 U.S. investigators

   $358,801research payments

6. A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

   Active, not recruiting · Phase 2 · Primary Sclerosing Cholangitis

   NCT05627362 · Ipsen Bioscience Inc. · 27 U.S. investigators

   $357,800research payments

7. FX Shoulder Prospective Clinical Study

   Recruiting · Osteoarthritis Shoulder

   NCT06078865 · Fx Shoulder Solutions, Inc · 0 U.S. investigators

   $356,900research payments

8. A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

   Terminated · Phase 1 · Advanced Solid Tumors

   NCT05904496 · Beone Medicines Ltd. · 3 U.S. investigators

   $354,193research payments

9. A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

   Active, not recruiting · Phase 3 · Epithelial Ovarian Cancer

   NCT03522246 · Pharmaand GmbH · 37 U.S. investigators

   $353,399research payments

10. A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume

    Recruiting · Phase 3 · Mid Face Volume Deficit

    NCT06734351 · AbbVie Inc. · 5 U.S. investigators

    $352,488research payments

11. Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

    Active, not recruiting · Phase 2 · SMARCB1-Deficient Malignancies

    NCT06444880 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $350,000research payments

12. A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

    Active, not recruiting · Phase 2 · Non-Hodgkin Lymphoma

    NCT05283720 · AbbVie Inc. · 12 U.S. investigators

    $348,987research payments

13. A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

    Completed · Phase 1 · Hepatic Impairment

    NCT05935033 · AbbVie Inc. · 3 U.S. investigators

    $347,268research payments

14. A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

    Active, not recruiting · Phase 1 · Respiratory Syncytial Virus

    NCT05743881 · ModernaTX, Inc. · 18 U.S. investigators

    $345,919research payments

15. TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

    Completed · Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    NCT04129502 · Takeda Pharmaceuticals U.S.A., Inc. · 4 U.S. investigators

    $345,862research payments

16. BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

    Completed · Phase 1 · Advanced Solid Tumor

    NCT04649385 · Beone Medicines USA, Inc. · 4 U.S. investigators

    $344,907research payments

17. Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites

    Completed · Phase 3 · Decompensated Cirrhosis and Ascites

    NCT03451292 · Grifols Therapeutics LLC · 7 U.S. investigators

    $344,551research payments

18. An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

    Terminated · Phase 3 · Crohn Disease

    NCT03467958 · Celgene Corporation · 25 U.S. investigators

    $343,690research payments

19. STRIVE Post-Market Registry Study

    Recruiting · Emphysema

    NCT04302272 · Gyrus Acmi, Inc. · 9 U.S. investigators

    $341,933research payments

20. First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

    Terminated · Phase 1 · Neoplasm Malignant

    NCT04401020 · Sanofi US Services Inc. · 2 U.S. investigators

    $340,907research payments

21. A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

    Recruiting · Phase 1, Phase 2 · Hemophilia B

    NCT06379789 · Regeneron Pharmaceuticals, Inc. · 6 U.S. investigators

    $340,867research payments

22. Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

    Terminated · Phase 3 · Metastatic Non-Squamous Non-Small Cell Lung Cancer

    NCT03906071 · Mirati Therapeutics, Inc. · 50 U.S. investigators

    $339,747research payments

23. A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

    Active, not recruiting · Phase 1 · Relapsed/Refractory Multiple Myeloma

    NCT05308654 · AbbVie Inc. · 14 U.S. investigators

    $338,765research payments

24. A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

    Completed · Phase 3 · Ulcerative Colitis

    NCT05784246 · Eli Lilly and Company · 12 U.S. investigators

    $338,036research payments

25. Patient Retrospective Outcomes (PRO)

    Recruiting · Chronic Pain

    NCT01550575 · Boston Scientific Corporation · 18 U.S. investigators

    $337,935research payments

26. Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

    Active, not recruiting · Phase 3 · Amyloid Cardiomyopathy, Transthyretin-Related

    NCT04988386 · Eidos Therapeutics, Inc. · 26 U.S. investigators

    $337,921research payments

27. Folfox+Irinotecan+Chemort In Esophageal Cancer

    Recruiting · Phase 2 · Gastroesophageal Junction Adenocarcinoma

    NCT04656041 · Ipsen Biopharmaceuticals, Inc · 2 U.S. investigators

    $336,318research payments

28. A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

    Completed · Phase 2, Phase 3 · SARS-CoV-2

    NCT04796896 · ModernaTX, Inc. · 2 U.S. investigators

    $333,228research payments

29. A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

    Recruiting · Phase 3 · Chronic Migraine in Children

    NCT04965675 · H. Lundbeck A S · 17 U.S. investigators

    $332,859research payments

30. A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis

    Completed · Phase 2 · Psoriasis

    NCT06073119 · Sanofi US Services Inc. · 12 U.S. investigators

    $332,852research payments

31. Point of Care Respiratory Pathogen Testing for Antibiotic Stewardship in Primary Care

    Enrolling by invitation · Not applicable · Upper Respiratory Infection

    NCT06765135 · Biomerieux Inc · 1 U.S. investigator

    $332,662research payments

32. A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

    Recruiting · Phase 1 · Advanced or Metastatic Solid Tumor Malignancies

    NCT06258304 · Grifols Shared Services North America, Inc. · 1 U.S. investigator

    $330,000research payments

33. A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM

    Recruiting · Phase 3 · Macular Telangiectasia Type 2

    NCT06397131 · Neurotech Pharmaceuticals, Inc. · 4 U.S. investigators

    $328,531research payments

34. A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

    Terminated · Phase 1, Phase 2 · Metastasis

    NCT04009681 · Sanofi US Services Inc. · 4 U.S. investigators

    $327,689research payments

35. Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

    Active, not recruiting · Phase 1 · Non-Hodgkin's Lymphoma

    NCT06667687 · AbbVie Inc. · 7 U.S. investigators

    $322,557research payments

36. NEUROMARK Randomized Controlled Trial

    Completed · Not applicable · Chronic Rhinitis

    NCT06128200 · Neurent Medical Limited · 0 U.S. investigators

    $321,249research payments

37. DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

    Terminated · Phase 2 · Non-Small Cell Lung Cancer

    NCT03505710 · Daiichi Sankyo Inc. · 3 U.S. investigators

    $321,083research payments

38. A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

    Active, not recruiting · Phase 2 · Recurrent Ovarian Cancer

    NCT06365853 · AbbVie Inc. · 12 U.S. investigators

    $320,889research payments

39. A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

    Active, not recruiting · Phase 3 · Fibrodysplasia Ossificans Progressiva

    NCT05394116 · Regeneron Pharmaceuticals, Inc. · 2 U.S. investigators

    $320,030research payments

40. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures

    Terminated · Phase 2 · Electroencephalographic Neonatal Seizures

    NCT04519645 · UCB SA · 13 U.S. investigators

    $320,013research payments

41. A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

    Recruiting · Phase 3 · Follicular Lymphoma

    NCT06911502 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $319,963research payments

42. BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

    Recruiting · Phase 2 · Mantle Cell Lymphoma

    NCT06854003 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $317,726research payments

43. A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

    Terminated · Phase 1 · Duchenne Muscular Dystrophy

    NCT06597656 · Sarepta Therapeutics, Inc. · 3 U.S. investigators

    $316,848research payments

44. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

    Active, not recruiting · Phase 2 · Hidradenitis Suppurativa

    NCT05139602 · AbbVie Inc. · 16 U.S. investigators

    $316,732research payments

45. A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

    Active, not recruiting · Phase 1, Phase 2 · Advanced Solid Tumor

    NCT06833008 · Ipsen Pharma Sas · 6 U.S. investigators

    $315,201research payments

46. First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

    Recruiting · Phase 1 · Solid Tumors

    NCT06644755 · Daiichi Sankyo Inc. · 3 U.S. investigators

    $315,088research payments

47. Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

    Terminated · Phase 3 · Acute-On-Chronic Liver Failure

    NCT03702920 · Grifols Therapeutics LLC · 8 U.S. investigators

    $312,506research payments

48. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

    Active, not recruiting · Phase 3 · Rheumatoid Arthritis

    NCT02629159 · AbbVie Inc. · 31 U.S. investigators

    $312,434research payments

49. A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    Active, not recruiting · Phase 2 · Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma

    NCT06628310 · AbbVie Inc. · 7 U.S. investigators

    $310,954research payments

50. A First-In-Human Study of LY3985297 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT06395012 · Eli Lilly and Company · 2 U.S. investigators

    $310,337research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.